Siren »

Tourmaline Bio shares owned by Siren

Quarter-by-quarter ownership of Tourmaline Bio (TRML) shares owned by Siren from 13F filings

Historical chart of Siren investment in Tourmaline Bio

Tip: Access up to 7 years of quarterly data

All positions including Tourmaline Bio held by Siren consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Tourmaline Bio by Siren

Quarter filed Position value Share count Share price at filing
2024-09-30 $2.4M 91k 25.71

More positions owned by Siren

Kymera Therapeutics (KYMR)
Beigene Sponsored Adr
Scholar Rock Hldg Corp (SRRK)
Bicara Therapeutics (BCAX)
Argenx SE Sponsored Adr (ARGX)
Crinetics Pharmaceuticals In (CRNX)
Avidity Biosciences Ord (RNA)
Apellis Pharmaceuticals (APLS)
Lexicon Pharmaceuticals Com New (LXRX)
Igm Biosciences (IGMS)
Centessa Pharmaceuticals Sponsored Ads (CNTA)
Ascendis Pharma A/S Sponsored Adr (ASND)
Silence Therapeutics Ads (SLN)
Arrowhead Pharmaceuticals (ARWR)
WAVE Life Sciences SHS (WVE)

View all positions for Siren

Top funds holding Tourmaline Bio

RA Capital Management
BlackRock
Blue Owl Capital Holdings
Jennison Associates
Qiming U.S. Ventures Management
Nantahala Capital Management
Geode Capital Management
Citadel Advisors
Point72 Asset Management
Pictet Asset Management Holding SA
Schonfeld Strategic Advisors
Northern Trust
Alyeska Investment Group
Woodline Partners
Nan Fung Group Holdings

View all funds holding Tourmaline Bio